HK1202067A1 - Therapeutic agents comprising insulin amino acid sequences - Google Patents
Therapeutic agents comprising insulin amino acid sequences Download PDFInfo
- Publication number
- HK1202067A1 HK1202067A1 HK15102642.1A HK15102642A HK1202067A1 HK 1202067 A1 HK1202067 A1 HK 1202067A1 HK 15102642 A HK15102642 A HK 15102642A HK 1202067 A1 HK1202067 A1 HK 1202067A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- amino acid
- acid sequences
- therapeutic agents
- insulin amino
- acid sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161563985P | 2011-11-28 | 2011-11-28 | |
| US201161563985P | 2011-11-28 | ||
| PCT/US2012/066795 WO2013082116A1 (en) | 2011-11-28 | 2012-11-28 | Therapeutic agents comprising insulin amino acid sequences |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1202067A1 true HK1202067A1 (en) | 2015-09-18 |
Family
ID=48536000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15102642.1A HK1202067A1 (en) | 2011-11-28 | 2012-11-28 | Therapeutic agents comprising insulin amino acid sequences |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20130150291A1 (enExample) |
| EP (1) | EP2785367A4 (enExample) |
| JP (1) | JP2014534265A (enExample) |
| KR (1) | KR20140103985A (enExample) |
| CN (1) | CN104080473A (enExample) |
| AU (1) | AU2012346058A1 (enExample) |
| BR (1) | BR112014012789A2 (enExample) |
| CA (1) | CA2856967A1 (enExample) |
| HK (1) | HK1202067A1 (enExample) |
| IL (1) | IL232781A0 (enExample) |
| MX (1) | MX2014006391A (enExample) |
| RU (1) | RU2014126244A (enExample) |
| SG (1) | SG11201402661TA (enExample) |
| WO (1) | WO2013082116A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8841255B2 (en) * | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
| US20130172274A1 (en) | 2005-12-20 | 2013-07-04 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
| WO2009158704A2 (en) | 2008-06-27 | 2009-12-30 | Duke University | Therapeutic agents comprising elastin-like peptides |
| EP2717902B1 (en) | 2011-06-06 | 2018-01-24 | Phasebio Pharmaceuticals, Inc. | Use of modified vasoactive intestinal peptides in the treatment of hypertension |
| US20150290328A1 (en) | 2012-11-20 | 2015-10-15 | Phasebio Pharmaceuticals, Inc. | Formulations of active agents for sustained release |
| JP2016505627A (ja) * | 2013-01-15 | 2016-02-25 | フェーズバイオ ファーマシューティカルズ，インコーポレイテッド | 治療剤、組成物、および血糖コントロールのための方法 |
| ES2818824T3 (es) | 2014-05-08 | 2021-04-14 | Phasebio Pharmaceuticals Inc | Composiciones que comprenden una proteína de fusión de VIP-ELP para su uso en el tratamiento de fibrosis quística |
| JPWO2015178466A1 (ja) * | 2014-05-21 | 2017-04-20 | 味の素株式会社 | フィブロイン様タンパク質の製造法 |
| WO2016081884A2 (en) * | 2014-11-21 | 2016-05-26 | Phasebio Pharmaceuticals, Inc. | Elp fusion proteins for controlled and sustained release |
| CN114652817A (zh) | 2015-02-09 | 2022-06-24 | 费斯生物制药公司 | 用于治疗肌肉疾病和病症的方法和组合物 |
| TW201718627A (zh) | 2015-06-11 | 2017-06-01 | 梅茲製藥有限兩合公司 | 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞 |
| EP3124495A1 (en) * | 2015-07-31 | 2017-02-01 | Centre National de la Recherche Scientifique (C.N.R.S.) | Derivatives of elastin-like polypeptides and uses thereof |
| WO2017024182A1 (en) | 2015-08-04 | 2017-02-09 | Duke University | Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same |
| CN105061566A (zh) * | 2015-09-05 | 2015-11-18 | 苏州普罗达生物科技有限公司 | 拟胰岛素多肽及其应用 |
| KR20170036643A (ko) * | 2015-09-24 | 2017-04-03 | 한미약품 주식회사 | 인슐린의 제조 방법 |
| KR101815080B1 (ko) * | 2015-11-03 | 2018-01-04 | 재단법인대구경북과학기술원 | 췌장소도세포 및 엘라스틴 유사 인공 세포외 기질을 포함하는 당뇨병 치료용 약학적 조성물 |
| US11752213B2 (en) | 2015-12-21 | 2023-09-12 | Duke University | Surfaces having reduced non-specific binding and antigenicity |
| EP3423084B1 (en) | 2016-03-02 | 2021-09-01 | Merz Pharma GmbH & Co. KGaA | Composition comprising botulinum toxin |
| EP3448872A4 (en) | 2016-04-27 | 2019-12-11 | The Regents of the University of California | PREPARATION OF FUNCTIONAL HOMOCYSTEINRESTES IN POLYPEPTIDES AND PEPTIDES |
| US20190218274A1 (en) | 2016-05-06 | 2019-07-18 | Phasebio Pharmaceuticals, Inc. | Elp fusion proteins for controlled and sustained release |
| US11467156B2 (en) | 2016-06-01 | 2022-10-11 | Duke University | Nonfouling biosensors |
| WO2018057847A1 (en) | 2016-09-23 | 2018-03-29 | Duke University | Unstructured non-repetitive polypeptides having lcst behavior |
| US11220467B2 (en) | 2017-01-11 | 2022-01-11 | Recycle Track Systems, Inc. | Indoor food waste fermentation and recycling process |
| US11648200B2 (en) | 2017-01-12 | 2023-05-16 | Duke University | Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly |
| WO2018213320A1 (en) | 2017-05-15 | 2018-11-22 | Duke University | Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents |
| US11952601B2 (en) | 2017-06-20 | 2024-04-09 | Merz Pharma Gmbh & Co. Kgaa | Recombinant botulinum toxin with increased duration of effect |
| WO2019006374A1 (en) | 2017-06-30 | 2019-01-03 | Duke University | ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-SENSITIVE BIOPOLYMER NETWORKS |
| WO2019007509A1 (en) | 2017-07-06 | 2019-01-10 | Merz Pharma Gmbh & Co. Kgaa | NOVEL RECOMBINANT BOTULINUM NEUROTOXINS WITH INCREASED DURATION |
| WO2019147954A1 (en) | 2018-01-26 | 2019-08-01 | Duke University | Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same |
| WO2019213150A1 (en) | 2018-04-30 | 2019-11-07 | Duke University | Stimuli-responsive peg-like polymer-based drug delivery platform |
| US11649275B2 (en) | 2018-08-02 | 2023-05-16 | Duke University | Dual agonist fusion proteins |
| CN111939244B (zh) | 2019-05-14 | 2024-08-06 | 阿莫生命科学有限公司 | 用于预防或治疗糖尿病并发症的药物组合物 |
| KR102456958B1 (ko) * | 2019-05-14 | 2022-10-21 | 강원대학교 산학협력단 | 당뇨병성 합병증의 예방 또는 치료용 약제학적 조성물 |
| US11512314B2 (en) | 2019-07-12 | 2022-11-29 | Duke University | Amphiphilic polynucleotides |
| US12435116B2 (en) | 2019-10-16 | 2025-10-07 | Clarence Hurt | Compounds, compositions, methods, and uses for treating insulin resistance, type 2 diabetes and metabolic syndrome |
| AU2020396647A1 (en) * | 2019-12-06 | 2022-07-07 | Ajinomoto Co., Inc. | Method for producing peptide having physiological activity, and peptide comprising short linker |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999024015A1 (en) * | 1997-11-12 | 1999-05-20 | Alza Corporation | Buffered drug formulations for transdermal electrotransport delivery |
| US7846445B2 (en) * | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
| ES2779992T3 (es) * | 2005-12-20 | 2020-08-21 | Univ Duke | Métodos y composiciones para suministrar agentes activos con propiedades farmacológicas potenciadas |
| WO2007095337A2 (en) * | 2006-02-15 | 2007-08-23 | Imclone Systems Incorporated | Antibody formulation |
| CN101616685B (zh) * | 2006-03-06 | 2013-07-24 | 阿穆尼克斯运营公司 | 非结构化重组聚合物和其应用 |
| WO2009158704A2 (en) * | 2008-06-27 | 2009-12-30 | Duke University | Therapeutic agents comprising elastin-like peptides |
| WO2010014689A1 (en) * | 2008-07-29 | 2010-02-04 | Phasebio Pharmaceuticals, Inc. | Pharmaceutical formulations comprising elastin-like proteins |
| MA33466B1 (fr) * | 2009-07-31 | 2012-07-03 | Sanofi Aventis Deutschland | Composition d'insuline à longue duree d'action |
| HUE054744T2 (hu) * | 2009-08-14 | 2021-12-28 | Phasebio Pharmaceuticals Inc | Módosított vazoaktív intesztinális peptidek |
-
2012
- 2012-11-28 SG SG11201402661TA patent/SG11201402661TA/en unknown
- 2012-11-28 RU RU2014126244A patent/RU2014126244A/ru not_active Application Discontinuation
- 2012-11-28 JP JP2014543618A patent/JP2014534265A/ja active Pending
- 2012-11-28 AU AU2012346058A patent/AU2012346058A1/en not_active Abandoned
- 2012-11-28 HK HK15102642.1A patent/HK1202067A1/xx unknown
- 2012-11-28 WO PCT/US2012/066795 patent/WO2013082116A1/en not_active Ceased
- 2012-11-28 US US13/687,776 patent/US20130150291A1/en not_active Abandoned
- 2012-11-28 EP EP12852785.0A patent/EP2785367A4/en not_active Withdrawn
- 2012-11-28 CA CA2856967A patent/CA2856967A1/en not_active Abandoned
- 2012-11-28 BR BR112014012789A patent/BR112014012789A2/pt not_active IP Right Cessation
- 2012-11-28 MX MX2014006391A patent/MX2014006391A/es unknown
- 2012-11-28 CN CN201280068260.1A patent/CN104080473A/zh active Pending
- 2012-11-28 KR KR1020147017232A patent/KR20140103985A/ko not_active Withdrawn
-
2014
- 2014-05-25 IL IL232781A patent/IL232781A0/en unknown
- 2014-06-13 US US14/304,617 patent/US20140364362A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2785367A1 (en) | 2014-10-08 |
| KR20140103985A (ko) | 2014-08-27 |
| CN104080473A (zh) | 2014-10-01 |
| JP2014534265A (ja) | 2014-12-18 |
| EP2785367A4 (en) | 2015-06-17 |
| RU2014126244A (ru) | 2016-01-27 |
| CA2856967A1 (en) | 2013-06-06 |
| IL232781A0 (en) | 2014-07-31 |
| US20140364362A1 (en) | 2014-12-11 |
| SG11201402661TA (en) | 2014-08-28 |
| AU2012346058A1 (en) | 2014-06-12 |
| MX2014006391A (es) | 2014-09-22 |
| US20130150291A1 (en) | 2013-06-13 |
| BR112014012789A2 (pt) | 2019-09-24 |
| WO2013082116A1 (en) | 2013-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1202067A1 (en) | Therapeutic agents comprising insulin amino acid sequences | |
| CY1125302T1 (el) | Συναγωνιστες γλυκαγονης και glp-1 για την αγωγη της παχυσαρκιας | |
| MX2014001372A (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico. | |
| WO2012168430A3 (en) | Polypeptides | |
| NZ705370A (en) | Fcγriib-specific fc region variant | |
| WO2012024620A3 (en) | Autotaxin inhibitors and uses thereof | |
| ECSP12011787A (es) | Polipéptidos para unión al "receptor para productos finales de glicosilación avanzada" así como composiciones y métodos que implican a los mismos | |
| MD4589B1 (ro) | Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C | |
| TN2014000134A1 (en) | Therapeutic peptides | |
| IN2012DN00971A (enExample) | ||
| MY167804A (en) | Treatment of degenerative joint disease | |
| WO2012006014A3 (en) | Multi-component pharmaceuticals for treating diabetes | |
| MX2014010433A (es) | Nueva forma cristalina de sulfato de sitagliptina. | |
| HK1202811A1 (en) | Compositions for preventing or treating adverse reactions of egfr inhibition | |
| WO2012076961A3 (en) | Carnosine - hyaluronic acid mixtures and their use | |
| AU2010353685A8 (en) | Novel glucagon like peptide analogs, composition, and method of use | |
| WO2014039074A3 (en) | Therapeutic compositions and related methods | |
| BRPI1015042A2 (pt) | unidades desencadeadoras ácido-lábeis | |
| MY163470A (en) | Curing process for concrete | |
| EP2588080A4 (en) | INJECTABLE PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF JOINTS | |
| MX349563B (es) | Formulacion farmaceutica de fenofibrato nanonizado. | |
| EA201391742A1 (ru) | Фармацевтическая композиция, включающая фексофенадин | |
| WO2013037985A8 (en) | Pharmaceutical combinations including anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders | |
| MX2012009537A (es) | Formas solidas que comprenden un derivado de ciclopropilamida. | |
| HK1197185A1 (en) | Methods and compositions for treatment of epithelial wounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CHRG | Changes in the register |
Free format text: ADDITION OF INVENTOR: PRIOR, CHRISTOPHER |